Effectiveness of First-line Therapy for Small Cell Lung Cancer with IO Chemotherapy

被引：0
|
作者：
Grohe, C. [1 ]
机构：
[1] Elk Ev Lungenklin, Klin Pneumol, Berlin, Germany
来源：
PNEUMOLOGIE | 2022年 / 76卷
关键词：
D O I：
10.1055/s-0042-1747799
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Po 249
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [21] Non-small-cell lung cancer progression after first-line chemotherapy.
    Lara Jr. P.N.
    Lau D.H.
    Gandara D.R.
    Current Treatment Options in Oncology, 2002, 3 (1) : 53 - 58
  • [22] Neutropenic enterocolitis during first-line chemotherapy with carboplatin and etoposide in small cell lung cancer
    Baandrup, Louise
    Hauggaard, Anders
    Winberg, Birgitte H.
    Holm, Bente
    ACTA ONCOLOGICA, 2011, 50 (03) : 465 - 467
  • [23] Response of asymptornatic brain metastases of small cell lung cancer to systemic (first-Line) chemotherapy
    Seute, T
    Leffers, P
    Ten Velde, GPM
    Wilmink, JT
    Twijnstra, A
    NEUROLOGY, 2005, 64 (06) : A26 - A26
  • [24] Response of asymptomatic brain metastases of small-cell lung cancer to first-line chemotherapy
    Seute, T
    Ten Velde, GP
    Wilmink, JT
    Twijnstra, A
    NEUROLOGY, 2001, 56 (08) : A410 - A410
  • [25] Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
    Xiang, Guiyuan
    Jiang, Tingting
    Gan, Lanlan
    Wu, Yuanlin
    Zhang, Ni
    Xing, Haiyan
    Su, Hui
    Li, Yanping
    Peng, Dan
    Ni, Rui
    Liu, Yao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [26] Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [27] First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
    Long, Rong
    Chen, Fangping
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [28] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [29] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
    Khan, Iftekhar
    Morris, Stephen
    Hackshaw, Allan
    Lee, Siow-Ming
    BMJ OPEN, 2015, 5 (07):
  • [30] Topotecan in the first-line treatment of small cell lung cancer
    Stewart, DJ
    ONCOLOGIST, 2004, 9 : 33 - 42
12345